Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta to Sell $6M in Stock in Private Offerings

Premium

Rosetta Genomics said this week that it has signed definitive agreements to sell an aggregate of $6 million in securities in concurrent private placement and registered direct offerings.

In the private placement, Rosetta will sell roughly 4.5 million ordinary shares at $0.60 each. Purchasers of the stock will also receive warrants to buy up to about 3.4 million more shares at $0.80 apiece.

In the direct offering, the company will sell approximately 5.5 million shares at $0.60 a share. Purchasers will also receive warrants to buy up to 2.7 million more shares at $0.80 per share.

Closing of the offerings is expected to occur around the end of February.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.